Edgar Gonzalez
General Practice · Miami, FLNPI 1801132121
Payments from drug & device makers
Across 900 payments — averaging $3352.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$1.4M
- AbbVie$442K
- Bayer$404K
- Teva Pharmaceuticals USA, Inc.$279K
- Genentech, Inc.$147K
- Akebia Therapeutics Inc$113K
- plus $238K from 13 others
Across 6 payments — averaging $110.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$666
What the payments were for
- Travel & lodging$4,04479%
- Food & beverage$1,10621%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 360 | $1,394,894 |
| AbbVie(2 entities) | 166 | $442,285 |
| Bayer | 170 | $403,687 |
| Teva Pharmaceuticals USA, Inc. | 4 | $278,575 |
| Genentech, Inc. | 37 | $146,836 |
| Akebia Therapeutics Inc | 89 | $112,986 |
| Galderma Laboratories, L.p. | 9 | $92,560 |
| Boehringer Ingelheim | 6 | $39,240 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 12 | $33,504 |
| Pfizer | 12 | $32,975 |
| Astrazeneca UK Limited | 5 | $31,732 |
| Boehringer Ingelheim France S.a.s. | 9 | $3,430 |
| Chiesi USA, Inc. | 3 | $2,715 |
| Genentech USA, Inc. | 3 | $859 |
| Boehringer Ingelheim International GmbH | 6 | $624 |
| Novo Nordisk | 3 | $52 |
| Johnson & Johnson | 3 | $52 |
| AstraZeneca | 2 | $34 |
| Gilead | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$129
How this compares
$3,017,059 in reported general payments places this provider in the 95th percentile of 6,901 general practice providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira PenAdalimumab | 11 | $76,538 |
| EliquisApixaban | 32 | $28,985 |
| BreynaBudesonide/Formoterol Fumarate | 14 | $3,228 |
| Tadalafil | 38 | $2,328 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $1,457 |
| Atorvastatin Calcium | 192 | $1,233 |
| Omeprazole | 128 | $1,221 |
| Levothyroxine Sodium | 93 | $951 |
| Enalapril Maleate | 74 | $940 |
| Losartan Potassium | 84 | $821 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 44 | $781 |
| Diclofenac Sodium | 35 | $706 |
| Pentoxifylline | 41 | $700 |
| Vitamin D2Ergocalciferol (Vitamin D2) | 193 | $631 |
| Donepezil Hcl | 87 | $587 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $32,975 | $28,98532 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,901 general practice providers in Florida.
Other general practice in Miami
- Jose CardonaMiami$71M
- Armando AcevedoMiami$15.2M
- Jorge AmayaMiami$14.2M
- Hector RodriguezMiami$12.8M
- Idalia AcostaMiami$11.4M
- Lilia Rodriguez AblesMiami$10.7M
- Omar BenitezMiami$6.9M
- Sara LlerenaMiami$6.3M
- Ana AcostaMiami$6.3M
- Gil Fernandez-YeraMiami$4.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.